Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was an incredibly positive day for the U.S. markets. Crude oil pushed higher on the day bringing up the Oil & Gas stocks, although there were a couple laggards in the group. For…
All Work
Chris Lange
Merrill Lynch’s Top 4 Internet Stocks for the Second Half of 2017
Merrill Lynch singled out a group in the tech sector that the firm believes will outperform going forward -- specifically, internet stocks.
Why Jefferies Is Taking a Backseat on IBM
IBM has struggled for year to get out of what some analysts have called a value trap. One analyst is slashing its target for the computer giant and sees further downside for the stock.
Meet the Newest Sports ETF
Sports fans rejoice. There is now an exchange traded fund that caters to this group: the ProSports Sponsors ETF.
Even More Concerns Surface About Apple Ahead of iPhone Launch
Apple reportedly is scrambling to put together its highly anticipated iPhone 8. The company seems to be facing a bug problem with its software. If these bugs persist it could cut into production and…
Why Ocular Therapeutix Shares Are Getting Crushed
Ocular Therapeutix shares were absolutely crushed on Wednesday after the company received less than favorable news from the FDA regarding its Dextenza in the treatment of ocular pain following ophthalmic surgery.
Is Now the Time for This Coal Miner to Come Public?
It is very surprising to see a coal company come forward and file to be publicly traded, considering the industry’s recent history.
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was a relatively volatile day for the markets seeing the major indices swing between positive and negative a couple times. Crude oil proved to be positive once again and sent most Oil &…
PetIQ Announces Potential Pricing for IPO
PetIQ intends to price more than 5 million shares in the range of $14 to $16 apiece in an initial public offering valued up to more than $104 million.
Meet Jefferies Top 12 Picks in the Roaring Biotech Industry
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has grown, and one analyst…
Why Snap’s Value Could Be Headed Even Lower
Camera app company Snap has been the subject of much controversy in the analyst community, with some calling for a turnaround while others are calling for it to sink even lower.
Why Arena Pharmaceuticals Is Knocking It Out of the Park
Shares of Arena Pharmaceuticals saw an incredible gain early Tuesday after the company reported positive results from its mid-stage trial in patients with pulmonary arterial hypertension.
Why This Key Analyst Believes That Apple’s New iPhone Won’t Live Up to the Hype
Most analysts are fairly bullish on their expectations for shipments of the upgraded iPhones. However, Deutsche Bank is taking a less-than bullish stance on Apple and what it can deliver for this next iPhone…
Torrid Files for IPO
This retailer of apparel for young, plus-size women has filed with the SEC regarding its initial public offering.
Barracuda Networks Sinks Despite Strong Q1 Revenue
Barracuda Networks reported mixed fiscal first-quarter financial results after the markets closed on Monday.
Monday’s Biggest Winners and Losers in the S&P 500
Monday was an interesting start to the week with U.S. broad markets closing higher after starting the day out negative. Crude oil helped with this boost and Oil & Gas as well as industrial…
How Much Will the New iPhone Cost? Maybe a Lot More Than You Think
The average price of the new iPhone might jump quite significantly, which could have huge implications on one hand for Apple hitting sales goals and on the other for consumers who would have to…
Why One Analyst Thinks Costco Might Be Next on Amazon’s Hit List
Costco saw its shares take a step back on Monday after some analysts soured on the stock, despite a strong same-store sales report for June.
Why Jefferies Sees Better Options Than Intel
According to one analyst, it’s not necessarily what’s under the hood at Intel that is the problem, but really the competition that it faces. Intel stands to lose most out of any of the…
Kala Pharmaceuticals Gears Up for IPO
Kala Pharmaceuticals intends to price 6 million shares in the range of $14 to $16 apiece in an initial public offering valued up to more than $110 million.